Pfizer pays $94 million to resolve allegations it made fraudulent patents to delay generic competition

To resolve allegations over Pfizer's use of fraudulent patents to delay generic competition for its anti-inflammatory drug celecoxib (Celebrex), the company has agreed to pay $94 million.

To resolve allegations over Pfizer's use of fraudulent patents to delay generic competition for its anti-inflammatory drug celecoxib (Celebrex), the company has agreed to pay $94 million. A lawsuit was brought by 32 direct purchasers of Celebrex in April and certified as a class action lawsuit in August, claiming that Pfizer attempted to revive its invalidated patent by making material misrepresentations to the U.S. Patent and Trademark Office (PTO). As a result, the PTO granted Pfizer a new patent based on this reportedly inaccurate information. Plaintiffs in the case say Pfizer filed a lawsuit against five generic manufacturers for infringing upon the fraudulently obtained patient to maintain a monopoly over the drug. The 32 direct purchasers alleged Pfizer's move to delay generic competition of the drug cost them hundreds of millions of dollars. The settlement agreement, made on November 22, still requires official court approval.